This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Nora Pencheva, Ph.D.
Associate Director, Translational Medicine Lead at Genmab B.V.

Profile

Nora Pencheva, PhD joined Genmab in 2017 as Senior Scientist and currently serves as Associate Director in the Translational Medicine department at Genmab. She is the Translational Medicine Lead on DuoBody®-PD-L1x4-1BB (GEN1046) jointly developed by Genmab and BioNTech for the treatment of solid tumors. Prior to joining Genmab, Dr. Pencheva was an HFSP postdoctoral fellow at the Netherlands Cancer Institute. She completed her PhD training in Molecular and Cellular Biology at the Rockefeller University in New York and received the Harold M. Weintraub award from the Fred Hutchinson Cancer Research Center for outstanding achievements during her graduate research. Dr. Pencheva holds a BSc degree in Neuroscience from Kenyon College, OH USA.

Agenda Sessions

  • Peripheral and Tumoral Immune Activity in the Expansion Part of the First-in-Human DuoBody®-PD-L1x4-1BB (GEN1046) Trial

    10:20